Covered recipient · General Payments record
WILLIAM A GREISNER
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,755.27
121 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,657.08 | 120 |
| Education | $98.19 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $395.59 | 10 |
| AstraZeneca Pharmaceuticals LP | $386.38 | 15 |
| GlaxoSmithKline, LLC. | $321.08 | 18 |
| PFIZER INC. | $266.87 | 18 |
| GENZYME CORPORATION | $245.03 | 14 |
| BioCryst US Sales Co., LLC | $192.87 | 3 |
| CSL Behring | $185.75 | 9 |
| Novartis Pharmaceuticals Corporation | $117.37 | 3 |
| Genentech USA, Inc. | $98.74 | 5 |
| ADMA BioManufacturing LLC | $96.42 | 4 |
| kaleo, Inc. | $95.18 | 5 |
| Teva Pharmaceuticals USA, Inc. | $89.79 | 5 |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.84 | 3 |
| Blueprint Medicines Corporation | $59.44 | 2 |
| Incyte Corporation | $39.76 | 2 |
| Amgen Inc. | $30.25 | 2 |
| SANOFI-AVENTIS U.S. LLC | $29.63 | 1 |
| Octapharma USA, Inc. | $19.02 | 1 |
| Covis Pharma GmBH | $17.26 | 1 |
Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WILLIAM A GREISNER
NPI 1720095334 · CMS profile ID 259552
Allopathic & Osteopathic Physicians / Allergy & Immunology
LEXINGTON, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1720095334?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720095334?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720095334?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- WILLIAM A GREISNER, NPI 1720095334, CMS profile ID 259552, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–121 of 121 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1720095334?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
121 matching records · $2,755.27 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–121 of 121.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.18 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893714603 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.14 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927185295 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.44 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955646537 | CMS |
| GlaxoSmithKline, LLC. | $24.71 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945040589 | CMS |
| GENZYME CORPORATION | $17.07 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938815883 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.39 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920262621 | CMS |
| PFIZER INC. | $14.48 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949624753 | CMS |
| CSL Behring | $16.99 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940918073 | CMS |
| GENZYME CORPORATION | $8.00 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938815889 | CMS |
| Genentech USA, Inc. | $18.49 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950799153 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.28 | 01/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927185289 | CMS |
| GlaxoSmithKline, LLC. | $5.04 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945040595 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.40 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920251353 | CMS |
| kaleo, Inc. | $17.28 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941043023 | CMS |
| GlaxoSmithKline, LLC. | $22.28 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945040609 | CMS |
| CSL Behring | $19.71 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940918055 | CMS |
| Teva Pharmaceuticals USA, Inc. | $16.34 | 01/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954569957 | CMS |
| ADMA BioManufacturing LLC | $22.90 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933559255 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.07 | 01/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920237771 | CMS |
| AstraZeneca Pharmaceuticals LP | $117.61 | 01/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 920233361 | CMS |
| ADMA BioManufacturing LLC | $17.81 | 01/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933559251 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $265,608.56 | 37 |
| PY2024 | Principal investigator | $306,474.85 | 35 |
| PY2023 | Principal investigator | $431,332.11 | 50 |
| PY2022 | Principal investigator | $304,278.58 | 60 |
| PY2021 | Principal investigator | $160,229.56 | 37 |
| PY2020 | Principal investigator | $95,780.23 | 3 |
| PY2019 | Principal investigator | $197,779.47 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
37 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,359.28 | 12/24/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184280306 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $25,955.10 | 12/23/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192147196 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.05 | 12/19/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278760 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,595.50 | 11/25/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192181820 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.05 | 11/19/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,325.57 | 10/17/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251185 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,395.30 | 10/02/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192181815 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,722.01 | 09/18/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA SPECIALISTS PSC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192147182 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,298.53 | 09/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237002 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.05 | 09/15/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237004 |
| Principal investigator 1 | AstraZeneca UK Limited | $13,783.65 | 08/20/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma | No dispute reported | 06/30/2026 | 1185539765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $215.05 | 08/20/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228895 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,264.81 | 08/20/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228909 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,158.21 | 08/01/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192147199 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,232.00 | 08/01/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192181811 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,315.00 | 07/29/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185539759 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,409.26 | 07/22/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA SPECIALISTS PSC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192147192 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,593.72 | 07/14/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214936 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,821.23 | 07/14/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214938 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $590.49 | 06/27/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211717 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $243.00 | 05/02/2025 | Non-covered Recipient Entity BLUEGRASS ALLERGY CARE | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | No dispute reported | 06/30/2026 | 1192181823 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,828.18 | 04/24/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA SPECIALISTS PSC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192147187 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $30,915.00 | 04/24/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047542 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $477.00 | 04/11/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192143447 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,380.00 | 04/11/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192143450 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $650.00 | 04/11/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192147179 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,831.00 | 04/09/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185539761 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $790.00 | 04/02/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192143455 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $756.00 | 04/02/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192143459 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,370.00 | 04/02/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192143463 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,288.00 | 04/02/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192147172 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,385.00 | 04/02/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192147176 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 03/06/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244047574 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,679.06 | 02/24/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States | No dispute reported | 06/30/2026 | 1185539755 |
| Principal investigator 1 | Eli Lilly and Company | $83,723.34 | 01/15/2025 | Non-covered Recipient Entity MERCY HEALTH - LOURDES HOSPITAL LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187886096 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,200.00 | 01/03/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185539757 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $33,208.52 | 01/03/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA ASSOCIATES PSC | The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod | No dispute reported | 06/30/2026 | 1185539763 |